Feng S, Zhang T, Ke W, Xiao Y, Guo Z, Lu C
Life Med. 2025; 1(2):196-206.
PMID: 39871935
PMC: 11749281.
DOI: 10.1093/lifemedi/lnac008.
Rzhanova L, Alpeeva E, Aleksandrova M
Cells. 2024; 13(23).
PMID: 39682681
PMC: 11640686.
DOI: 10.3390/cells13231931.
Oh C, Nakamura T, Zhang X, Lipton S
Neuron. 2024; 112(23):3823-3850.
PMID: 39515322
PMC: 11624102.
DOI: 10.1016/j.neuron.2024.10.013.
Umeyama T, Matsuda T, Nakashima K
Cells. 2024; 13(8.
PMID: 38667322
PMC: 11049106.
DOI: 10.3390/cells13080707.
Arai K, Saito F, Miyazaki M, Kushige H, Izu Y, Maeta N
Int J Mol Sci. 2023; 24(21).
PMID: 37958789
PMC: 10648228.
DOI: 10.3390/ijms242115804.
An engineered Sox17 induces somatic to neural stem cell fate transitions independently from pluripotency reprogramming.
Weng M, Hu H, Graus M, Tan D, Gao Y, Ren S
Sci Adv. 2023; 9(34):eadh2501.
PMID: 37611093
PMC: 10446497.
DOI: 10.1126/sciadv.adh2501.
Induced pluripotent stem cell-derived and directly reprogrammed neurons to study neurodegenerative diseases: The impact of aging signatures.
Aversano S, Caiazza C, Caiazzo M
Front Aging Neurosci. 2023; 14:1069482.
PMID: 36620769
PMC: 9810544.
DOI: 10.3389/fnagi.2022.1069482.
Generation of neural organoids for spinal-cord regeneration via the direct reprogramming of human astrocytes.
Xu J, Fang S, Deng S, Li H, Lin X, Huang Y
Nat Biomed Eng. 2022; 7(3):253-269.
PMID: 36424465
DOI: 10.1038/s41551-022-00963-6.
The therapeutic prospects and challenges of human neural stem cells for the treatment of Alzheimer's Disease.
Yue C, Feng S, Chen Y, Jing N
Cell Regen. 2022; 11(1):28.
PMID: 36050613
PMC: 9437172.
DOI: 10.1186/s13619-022-00128-5.
Isolation and comparison of neural stem cells from the adult rat brain and spinal cord canonical neurogenic niches.
Schiro L, Bauer U, Sandvig A, Sandvig I
STAR Protoc. 2022; 3(2):101426.
PMID: 35693206
PMC: 9184809.
DOI: 10.1016/j.xpro.2022.101426.
Electroactive Scaffolds to Improve Neural Stem Cell Therapy for Spinal Cord Injury.
Mutepfa A, Hardy J, Adams C
Front Med Technol. 2022; 4:693438.
PMID: 35274106
PMC: 8902299.
DOI: 10.3389/fmedt.2022.693438.
OCT4-induced oligodendrocyte progenitor cells promote remyelination and ameliorate disease.
Yun W, Choi K, Hwang I, Zheng J, Park M, Hong W
NPJ Regen Med. 2022; 7(1):4.
PMID: 35027563
PMC: 8758684.
DOI: 10.1038/s41536-021-00199-z.
Adult Human Multipotent Neural Cells Could Be Distinguished from Other Cell Types by Proangiogenic Paracrine Effects via MCP-1 and GRO.
Kim S, Pyeon H, Bae Y, Nam H, Kim C, Lee S
Stem Cells Int. 2021; 2021:6737288.
PMID: 34434240
PMC: 8380502.
DOI: 10.1155/2021/6737288.
Direct Neuronal Reprogramming: Bridging the Gap Between Basic Science and Clinical Application.
Vasan L, Park E, David L, Fleming T, Schuurmans C
Front Cell Dev Biol. 2021; 9:681087.
PMID: 34291049
PMC: 8287587.
DOI: 10.3389/fcell.2021.681087.
Generation of biologically active recombinant human OCT4 protein from .
Dey C, Thool M, Bhattacharyya S, Sudhagar S, Thummer R
3 Biotech. 2021; 11(5):207.
PMID: 33927995
PMC: 8032842.
DOI: 10.1007/s13205-021-02758-z.
Small molecules efficiently reprogram apical papilla stem cells into neuron-like cells.
Chen Q, Yuan C, Jiang S, Heng B, Zou T, Shen Z
Exp Ther Med. 2021; 21(6):546.
PMID: 33850518
PMC: 8027758.
DOI: 10.3892/etm.2021.9978.
Cardiac fibrosis: Myofibroblast-mediated pathological regulation and drug delivery strategies.
Liu M, Lopez de Juan Abad B, Cheng K
Adv Drug Deliv Rev. 2021; 173:504-519.
PMID: 33831476
PMC: 8299409.
DOI: 10.1016/j.addr.2021.03.021.
Direct Reprogramming of Somatic Cells to Neurons: Pros and Cons of Chemical Approach.
Mollinari C, Merlo D
Neurochem Res. 2021; 46(6):1330-1336.
PMID: 33666839
PMC: 8084785.
DOI: 10.1007/s11064-021-03282-5.
Phenotypic technologies in stem cell biology.
Vandana J, Lacko L, Chen S
Cell Chem Biol. 2021; 28(3):257-270.
PMID: 33651977
PMC: 7979494.
DOI: 10.1016/j.chembiol.2021.02.001.
How to reprogram human fibroblasts to neurons.
Xu Z, Su S, Zhou S, Yang W, Deng X, Sun Y
Cell Biosci. 2020; 10:116.
PMID: 33062254
PMC: 7549215.
DOI: 10.1186/s13578-020-00476-2.